Methotrexate Monitoring Target Trial Emulation

The goal of this retrospective, observational study is to learn more about the risks and benefits of methotrexate lab monitoring. The main question it aims to answer is: \- Is reduced methotrexate lab monitoring non-inferiorly safe when compared to standard lab monitoring? Differences in end-organ damage and/or death will be compared between participants who have previously been treated with methotrexate for various rheumatic diseases and have undergone varying intervals of methotrexate lab monitoring

NCT Number	NCT07512401
Lead Sponsor	Mayo Clinic Collaborators: Rochester Epidemiology Project, National Institute on Aging (NIA), National Center for Advancing Translational Sciences (NCATS)
Conditions	Rheumatic Diseases
Enrollment	2,414 participants
Start Date	2012-01-01
Primary Completion	2025-12-31 (estimated)
Study Completion	2025-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-06